An Ontario scientist has developed the first cancer therapy to inhibit an aggressive form of leukemia by targeting a protein, CD123, that is on the surface of cancer stem cells, which are responsible for cancer growth. Dr. John Dick, a senior scientist at the Ontario Institute for Cancer Research, is working on clinical trials with other researchers in Australia. The head of OICR suggests that this discovery could help treat other types of tumors too. This is exciting because cancer stem cells are what can lead to a recurrence of the disease. Targeting them may prevent that devastating possibility.